Amphastar makes injectable, inhaled and nasal medicines, including generics and proprietary products, sold to patients and healthcare providers. AMPH reports earnings on Thu, Nov 5, 2026.
Prices, price targets and earnings estimates for AMPH are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in AMPH in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AMPH is in one of them and how their past AMPH trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals is a pharmaceutical company based in Rancho Cucamonga, California. It develops, manufactures and sells injectable, inhalation and nasal drug products, including generic and proprietary medicines, as well as active pharmaceutical ingredients. Its best-known products include BAQSIMI, a nasal glucagon for severe low blood sugar in people with diabetes, and Primatene MIST, an asthma inhaler sold without a prescription. Its customers include patients and healthcare providers in the United States and in international markets.
